Table 3 Changes from baseline to week 24 in SBP, BMI, and ePV
Variables | Canagliflozin | Glimepiride |
|---|---|---|
SBP, mmHg | ||
 All patients | (n = 107) | (n = 113) |
  Baseline | 125.1 (122.1 to 128.2) | 124.7 (121.8 to 127.7) |
  Week 24 | 122.4 (119.3 to 125.4) | 123.8 (120.8 to 126.8) |
  Absolute change from baseline to week 24 | − 2.74 (− 5.28 to − 0.20) | − 0.92 (− 3.39 to 1.55) |
 Naïve | (n = 38) | (n = 43) |
  Baseline | 126.2 (121.4 to 131.0) | 123.8 (119.3 to 128.4) |
  Week 24 | 124.1 (119.3 to 128.9) | 121.5 (116.9 to 126.0) |
  Absolute change from baseline to week 24 | − 2.03 (− 6.59 to 2.54) | − 2.37 (− 6.67 to 1.92) |
 Non-naïve | (n = 69) | (n = 70) |
  Baseline | 124.5 (120.6 to 128.5) | 125.3 (121.4 to 129.2) |
  Week 24 | 121.4 (117.5 to 125.3) | 125.2 (121.3 to 129.1) |
  Absolute change from baseline to week 24 | − 3.13 (− 6.20 to − 0.06) | − 0.03 (− 3.07 to 3.02) |
 Non-naïve metformin user | (n = 18) | (n = 26) |
  Baseline | 121.2 (113.6 to 128.9) | 122.6 (116.2 to 129.0) |
  Week 24 | 120.0 (112.3 to 127.7) | 122.1 (115.7 to 128.5) |
  Absolute change from baseline to week 24 | − 1.22 (− 7.74 to 5.29) | − 0.50 (− 5.92 to 4.92) |
 Non-naïve DPP-4 inhibitor user | (n = 60) | (n = 59) |
  Baseline | 124.5 (120.2 to 128.8) | 125.0 (120.7 to 129.3) |
  Week 24 | 121.0 (116.7 to 125.3) | 125.5 (121.2 to 129.8) |
  Absolute change from baseline to week 24 | − 3.52 (− 6.78 to − 0.25) | 0.53 (− 2.77 to 3.82) |
BMI, kg/m2 | ||
 All patients | (n = 109) | (n = 109) |
  Baseline | 25.3 (24.6 to 26.1) | 25.7 (25.0 to 26.4) |
  Week 24 | 24.4 (23.6 to 25.1) | 25.8 (25.1 to 26.6) |
  Absolute change from baseline to week 24 | − 0.96 (− 1.20 to − 0.72) | 0.14 (− 0.09 to 0.38) |
 Naïve | (n = 39) | (n = 42) |
  Baseline | 24.4 (23.3 to 25.5) | 25.3 (24.3 to 26.3) |
  Week 24 | 23.5 (22.4 to 24.6) | 25.4 (24.3 to 26.4) |
  Absolute change from baseline to week 24 | − 0.93 (− 1.33 to − 0.53) | 0.05 (− 0.33 to 0.44) |
 Non-naïve | (n = 70) | (n = 67) |
  Baseline | 25.8 (24.9 to 26.8) | 25.9 (24.9 to 26.9) |
  Week 24 | 24.9 (23.9 to 25.8) | 26.1 (25.1 to 27.1) |
  Absolute change from baseline to week 24 | − 0.98 (− 1.29 to − 0.68) | 0.20 (− 0.11 to 0.51) |
 Non-naïve metformin user | (n = 18) | (n = 25) |
  Baseline | 27.6 (25.6 to 29.6) | 26.8 (25.1 to 28.5) |
  Week 24 | 26.5 (24.5 to 28.5) | 26.9 (25.2 to 28.6) |
  Absolute change from baseline to week 24 | − 1.14 (− 1.70 to − 0.59) | 0.09 (− 0.38 to 0.56) |
 Non-naïve DPP-4 inhibitor user | (n = 61) | (n = 56) |
  Baseline | 25.7 (24.6 to 26.7) | 26.3 (25.2 to 27.4) |
  Week 24 | 24.7 (23.6 to 25.7) | 26.5 (25.4 to 27.6) |
  Absolute change from baseline to week 24 | − 1.01 (− 1.36 to − 0.66) | 0.21 (− 0.15 to 0.57) |
ePV | ||
 All patients | (n = 107) | (n = 114) |
  Percent change from baseline to week 24, % | − 5.22 (− 7.66 to − 2.78) | 1.11 (− 1.25 to 3.47) |
 Naïve | (n = 38) | (n = 45) |
  Percent change from baseline to week 24, % | − 5.80 (− 9.97 to − 1.63) | − 0.17 (− 4.00 to 3.66) |
 Non-naïve | (n = 69) | (n = 69) |
  Percent change from baseline to week 24, % | − 4.90 (− 7.94 to − 1.86) | 1.95 (− 1.09 to 4.99) |
 Non-naïve metformin user | (n = 17) | (n = 26) |
  Percent change from baseline to week 24, % | − 6.53 (− 11.69 to − 1.38) | 1.86 (− 2.31 to 6.03) |
 Non-naïve DPP-4 inhibitor user | (n = 61) | (n = 58) |
  Percent change from baseline to week 24, % | − 4.08 (− 7.33 to − 0.83) | 1.77 (− 1.57 to 5.11) |